Research Topics
| Steven FishbaneSummaryAffiliation: Winthrop University Hospital Country: USA Publications
| Collaborators
|
Detail Information
Publications
The role of erythropoiesis-stimulating agents in the treatment of anemiaSteven Fishbane
Winthrop Nephrology Associates, 200 Old Country Rd, Suite 135, Mineola, NY 11501, USA
Am J Manag Care 16:S67-73. 2010..With the multiple safety issues involved in administering ESAs, our institution prefers to err on the side of caution until these concerns are resolved...- Safety in iron managementSteven Fishbane
Winthrop University Hospital, Mineola, NY 11501, USA
Am J Kidney Dis 41:18-26. 2003..This article reviews safety data surrounding the IV iron therapies... - A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysisSteven Fishbane
Winthrop University Hospital, Division of Nephrology and Hypertension, Mineola, NY 11501, USA
Am J Kidney Dis 55:307-15. 2010..Sevelamer carbonate powder for oral suspension is a new dosage form of sevelamer, which may be suited to once-daily dosing... - Erythropoiesis-stimulating agent treatment with full anemia correction: a new perspectiveSteven Fishbane
Department of Nephrology, Winthrop University Hospital, Mineola, NY 11501, USA
Kidney Int 75:358-65. 2009..We do not seek to propose that treatment with ESAs to higher Hgb targets is safe, but rather to use this outlier experience to gain knowledge and to generate hypotheses to be tested in future studies... - A randomized trial of iron deficiency testing strategies in hemodialysis patientsS Fishbane
Winthrop University Hospital, Mineola, and Brookdale Medical Center, Brooklyn, New York, USA
Kidney Int 60:2406-11. 2001..The purpose of this study was to compare iron management guided by serum ferritin and transferrin saturation to management guided by CHr... - Posttransplant anemia: the role of sirolimusSteven Fishbane
Division of Nephrology, Winthrop University Hospital, Mineola, New York 11501, USA
Kidney Int 76:376-82. 2009..Sirolimus, a mammalian target of rapamycin inhibitor, has been implicated as playing a special role in posttransplant anemia. This review considers anemia associated with sirolimus, including its presentation, mechanisms, and management... - The impact of standardized order sets and intensive clinical case management on outcomes in community-acquired pneumoniaSteven Fishbane
Winthrop University Hospital, Mineola, New York, USA
Arch Intern Med 167:1664-9. 2007..The purpose of this study was to test whether the addition of intensive clinical case management to clinical guidelines could lead to a reduction in LOS that was not achievable by guidelines alone, while maintaining quality of care... - Improvement of hemodialysis catheter function with tenecteplase: a phase III, open-label study: TROPICS 4Steven Fishbane
Division of Nephrology, Winthrop University Hospital, 200 Old Country Rd, 135, Mineola, NY 11501, USA
J Thromb Thrombolysis 31:99-106. 2011..Tenecteplase administered as a 1 h or 1 h plus extended dwell was associated with improved HD catheter function in the TROPICS 4 trial... - Hypothesis: an erythropoietin honeymoon phase existsSteven Fishbane
Department of Medicine, Winthrop University Hospital, Mineola, New York 11501, USA
Kidney Int 78:646-9. 2010..We propose investigation of this phenomenon as it could lead to less expensive and safer approaches to treatment of CKD anemia... - Iron treatment: impact of safety issuesS Fishbane
Dialysis Services, Winthrop University Hospital, Mineola, NY 11501, USA
Am J Kidney Dis 32:S152-6. 1998..A recommendation is made, in contrast to the NKF-DOQI Guidelines, that i.v. iron should not be administered to hemodialysis patients if the serum ferritin level if greater than 500 ng/mL... - N-acetylcysteine in the prevention of radiocontrast-induced nephropathySteven Fishbane
Winthrop University Hospital, Mineola, New York 11501, USA
J Am Soc Nephrol 15:251-60. 2004..The following will review the individual studies, attempt to reconcile the divergent results, and propose future research needs... - N-acetylcysteine in the prevention of contrast-induced nephropathySteven Fishbane
Winthrop University Hospital, Mineola, New York 11501, USA
Clin J Am Soc Nephrol 3:281-7. 2008..Contrast-induced nephropathy (CIN) is a common clinical problem that is growing in importance as an increasing number of tests and procedures that utilize contrast media are performed... - Review of issues relating to iron and infectionS Fishbane
Division of Nephrology, Winthrop University Hospital, Mineola, NY, USA
Am J Kidney Dis 34:S47-52. 1999..There is no reason to alter current iron treatment strategies based on this literature... - What is needed to achieve a hemoglobin of 11.0-13.0 g/dl in end-stage renal diseaseSteven Fishbane
Winthrop University Hospital, 200 Old Country Road, Mineola, NY 11501, USA
Blood Purif 25:53-7. 2007..In addition, causes for diminished response and refractory anemia must be adequately evaluated. In this article, factors important for achieving Hb 11-13 g/dl in patients with ESRD are reviewed... - Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA)Nathan W Levin
Renal Research Institute, New York, NY 10128, USA
Lancet 370:1415-21. 2007..We aimed to compare the effectiveness of methoxy polyethylene glycol-epoetin beta, given intravenously at 2-week or 4-week intervals, with epoetin treatment one to three times per week for haemoglobin control in haemodialysis patients... - Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004Steven Fishbane
Winthrop University Hospital, Mineola, NY 11501, USA
Clin J Am Soc Nephrol 4:57-61. 2009..One contributing factor is iron deficiency, which may be particularly problematic during erythropoietin replacement therapy. The aim of this study was to examine the prevalence of iron deficiency in nondialysis CKD... - Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietinSteven Fishbane
Winthrop University Hospital, Mineola, New York, USA
Kidney Int 68:1337-43. 2005..Therapy, however, is often observed to be associated with recurrent cyclic fluctuations in hemoglobin levels. The purpose of this analysis was to describe the phenomenology of hemoglobin cycling during rHuEPO treatment... - Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targetsSteven Fishbane
Division of Nephrology, Department of Medicine, Winthrop University Hospital, Mineola, New York, USA
Clin J Am Soc Nephrol 2:1274-82. 2007.... - Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal diseaseAnatole Besarab
Division of Nephrology and Hypertension, Department o f Medicine, Henry Ford Hospital, Detroit, Michigan, USA
Clin Ther 29:626-39. 2007..A continuous erythropoietin receptor activator (C.E.R.A.) is currently in development for the treatment of anemia in patients with chronic renal disease (CRD) receiving or not receiving dialysis treatment... - Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failureSteven Fishbane
Winthrop University Hospital, Mineola, New York, USA
Kidney Int 77:175-7. 2010..We discuss an analysis by Szczech and colleagues of the effects of the higher hemoglobin target in CKD patients with diabetes mellitus or congestive heart failure... - Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trialSteven Fishbane
Winthrop University Hospital, Mineola, NY, USA
Am J Kidney Dis 54:647-52. 2009..Because of this, it could be helpful in treating patients with proteinuric renal diseases. The objective is to determine the effect of oral paricalcitol on protein excretion in patients with proteinuric chronic kidney disease... - Pharmacokinetic and pharmacodynamic properties of methoxy polyethylene glycol-epoetin beta are unaffected by the site of subcutaneous administrationSteven Fishbane
Winthrop University Hospital, Mineola, NY 11501, USA
J Clin Pharmacol 47:1390-7. 2007..The long half-life may permit effective anemia management with extended dosing intervals. Phase III clinical studies support the role of C.E.R.A. in managing anemia in patients with chronic kidney disease... - Iron supplementation in renal anemiaSteven Fishbane
Winthrop University Hospital, Mineola, NY, USA
Semin Nephrol 26:319-24. 2006..This review discusses the physiology of iron balance, derangements in iron balance in chronic kidney disease (CKD), and the diagnosis and treatment of iron deficiency in patients treated with rHuEPO... - Anemia treatment in chronic renal insufficiencySteven Fishbane
Winthrop University Hospital, Mineola, NY 11501, USA
Semin Nephrol 22:474-8. 2002..In this review, the benefits of anemia therapy are weighed against the risks and costs. On balance, it is concluded that anemia treatment meets a basic and important health need in these patients... - Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study resultsSteven Fishbane
Winthrop University Hospital, Department of Nephrology, Mineola, New York 11501, USA
Clin J Am Soc Nephrol 3:1718-25. 2008..ACHIEVE included a 6-week screening phase, including vitamin D washout, a 16-week dose-titration phase, and an 11-week assessment phase... - A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiographyJohn D Durham
Division of Nephrology, Department of Pharmacy, and Division of Cardiology, Winthrop-University Hospital, Mineola, New York, USA
Kidney Int 62:2202-7. 2002..1% NAC, 27.8% placebo; P = 0.09). The independent predictors of CN risk were diabetes mellitus and preexisting chronic renal insufficiency. CONCLUSIONS: NAC was not effective for the prevention of CN after cardiac angiography... - Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter studyRajnish Mehrotra
Division of Nephrology and Hypertension, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, California 90502, USA
Clin J Am Soc Nephrol 3:1437-45. 2008..This phase IIIb trial assessed the efficacy of increased dosages (3000 to 4500 mg/d) of reformulated lanthanum carbonate (500-, 750-, and 1000-mg tablets) in nonresponders to dosages of up to 3000 mg/d... - How can erythropoietin requirements be reduced in dialysis patients?Peter Kotanko
Renal Research Institute, New York, New York 10128, USA
Semin Dial 19:363-72. 2006 - Anemia in chronic kidney disease: status of new therapiesSteven Fishbane
Winthrop University Hospital, Mineola, New York, USA
Curr Opin Nephrol Hypertens 18:112-5. 2009..In addition, new drugs are being developed in both the ESA and intravenous (i.v.) iron classes... - Stabilizing hemoglobin levels: what's new in IV iron and anemia management?Steven Fishbane
Winthrop University Hospital, Mineola, NY, USA
Nephrol Nurs J 35:493-502. 2008..This article will help nephrology nurses better understand the balance between intravenous iron and erythropoiesis-stimulating agents to stabilize Hib levels... - Cytoprotection by darbepoetin/epoetin alfa in pig tubular and mouse mesangial cellsSteven Fishbane
Winthrop University Hospital, Division of Nephrology, Nephrology Laboratory, Mineola, New York 11501, USA
Kidney Int 65:452-8. 2004..Erythropoietin has recently been found to have cytoprotective effects in the central nervous system (CNS) and retina. The purpose of this study was to determine if darbepoetin alfa (DA) has cytoprotective properties in renal tissues... - Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patientsM V DeVita
Division of Nephrology, Department of Medicine, Lenox Hill Hospital, New York, NY, USA
Clin Nephrol 60:335-40. 2003.... - Sodium ferric gluconate complex in the treatment of iron deficiency for patients on dialysisS Fishbane
Department of Medicine, Winthrop University Hospital, Mineola, NY, USA
Am J Kidney Dis 37:879-83. 2001..The purpose of this review is to critically appraise the relevant literature and to synthesize the information into a strategy for clinical use of this drug... - More on renal salt wasting without cerebral disease: response to saline infusionSolomon Bitew
Division of Nephrology and Hypertension and Department of Medicine, Winthrop University Hospital, Mineola, New York, USA
Clin J Am Soc Nephrol 4:309-15. 2009..This controversy stems from overlapping clinical and laboratory findings and an inability to assess the volume status of these patients. The authors report another case of RSW without clinical cerebral disease and contrast it to SIADH... - Hyponatremia in community-acquired pneumoniaVinay Nair
Division of Nephrology, Winthrop University Hospital, Mineola, NY, USA
Am J Nephrol 27:184-90. 2007..The purpose of this study was to describe the incidence of hyponatremia in CAP and to analyze risk factors for its occurrence... - Tenecteplase for the improvement of blood flow rate in dysfunctional hemodialysis cathetersJesse Goldman
Temple University, Philadelphia, PA, USA
Clin Nephrol 77:55-61. 2012..We evaluated the efficacy and safety of the thrombolytic agent tenecteplase for the treatment of dysfunctional hemodialysis (HD) catheters... - Implications of neocytolysis for optimal management of anaemia in chronic kidney diseaseClarence P Alfrey
Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
Nephron Clin Pract 106:c149-56. 2007..Understanding neocytolysis and its relationship to fluctuating serum erythropoietin levels might help to better understand optimal treatment with erythropoietic agents... - Risk for acute renal failure in patients hospitalized for decompensated congestive heart failureHarini Chittineni
Winthrop University Hospital, Mineola, NY, USA
Am J Nephrol 27:55-62. 2007..The purpose of this study was to describe the incidence of ARF, to ascertain risk factors for its development, and to determine whether ARF impacts hospital outcomes... - Anemia and cardiovascular risk in the patient with kidney diseaseSteven Fishbane
Winthrop University Hospital, Mineola, NY, USA
Heart Fail Clin 4:401-10. 2008..To date, however, results from interventional studies have been disappointing in this regard. This article reviews the relationship between anemia in CKD and cardiovascular risk and explores current knowledge on ESA treatment... - Partial characterization of apoptotic factor in Alzheimer plasmaJ K Maesaka
Department of Medicine, Winthrop University Hospital, Mineola, New York 11501, USA
Am J Physiol 276:F521-7. 1999..Heating AD plasma to 56 degrees C did not deactivate the apoptotic factor. These results demonstrate the presence of an apoptotic factor in the plasma of patients with AD... - Refractory anemia in a patient with allergy to intravenous iron drugsS Fishbane
Winthrop University Hospital, Mineola, New York 11501, USA
Kidney Int 69:1910-3. 2006 - Renal salt wasting without cerebral disease: diagnostic value of urate determinations in hyponatremiaJ K Maesaka
Department of Medicine, Division of Nephrology and Hypertension, Winthrop-University Hospital, Mineola, New York 11501, USA
Kidney Int 71:822-6. 2007 - Cerebral salt-wasting syndrome: does it exist?J K Maesaka
Department of Medicine and Division of Nephrology and Hypertension, Winthrop University Hospital, Mineola, NY 11501, USA
Nephron 82:100-9. 1999..Evidence for the presence of a plasma natriuretic factor in CSWS is presented... - Regulation of renal urate excretion: a critical reviewJ K Maesaka
Department of Medicine, Winthrop University Hospital, Mineola, NY 11501, USA
Am J Kidney Dis 32:917-33. 1998..The natriuretic factor may have etiologic implications and diagnostic and therapeutic applications... - The new FDA label for erythropoietin treatment: how does it affect hemoglobin target?S Fishbane
Division of Nephrology, Winthrop University Hospital, Mineola, New York 11501, USA
Kidney Int 72:806-13. 2007..In this review, we consider the recent literature, the change in FDA warnings, and new National Kidney Foundation Anemia Guidelines. Suggestions for new Hb targets during erythropoiesis-stimulating agent treatment are presented... - A trial of darbepoetin alfa in type 2 diabetes and chronic kidney diseaseMarc A Pfeffer
Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
N Engl J Med 361:2019-32. 2009..Although darbepoetin alfa can effectively increase hemoglobin levels, its effect on clinical outcomes in these patients has not been adequately tested... - The QIP: will it improve dialysis care? An overviewSteven Fishbane
North Shore LIJ Health System, Great Neck, NY, USA
Nephrol News Issues 26:20, 22-4, 26. 2012..In this review we discuss the QIP, with a comprehensive explanation of measures and scoring procedure... - Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathyGeorge Bakris
Department of Medicine, Pritzker School of Medicine, University of Chicago, Chicago, Illinois, USA
Kidney Int 74:364-9. 2008..We conclude that telmisartan is superior to losartan in reducing proteinuria in hypertensive patients with diabetic nephropathy, despite a similar reduction in blood pressure... - Contribution of prostaglandin D2 synthase to progression of renal failure and dialysis dementiaJohn K Maesaka
Department of Medicine, Division of Nephrology and Hypertension, Winthrop University Hospital, Mineola, NY 11501, USA
Semin Nephrol 22:407-14. 2002.... - Self-assessed quality of life in peritoneal dialysis patientsS K Mittal
Division of Nephrology and Hypertension, Winthrop University Hospital, Mineola, NY, USA
Am J Nephrol 21:215-20. 2001..We sought to evaluate these indices in PD patients: (1) as measures of QOL, (2) predictors of QOL, (3) to study change in QOL over time, and (4) to compare QOL in PD vs. hemodialysis patients... - Self-assessed physical and mental function of haemodialysis patientsS K Mittal
Winthrop-University Hospital, Mineola, New York, USA
Nephrol Dial Transplant 16:1387-94. 2001..CONCLUSIONS: Self assessed physical and mental health of haemodialysis patients is markedly diminished compared to the general population and other chronic diseases... - Prostaglandin D(2) synthase induces apoptosis in pig kidney LLC-PK1 cellsJ K Maesaka
Department of Medicine, Division of Nephrology, Winthrop University Hospital, 222 Station Plaza North, Mineola, NY 11501, USA
Kidney Int 60:1692-8. 2001.... - Bone histology in patients with nephrotic syndrome and normal renal functionS K Mittal
Division of Nephrology, Winthrop University Hospital, Mineola, New York, USA
Kidney Int 55:1912-9. 1999..The prevalence of metabolic bone disease in patients with nephrotic syndrome (NS) at normal level of renal function remains uncertain... - Prostaglandin D2 synthase induces apoptosis in PC12 neuronal cellsL Ragolia
1Department of Medicine, Division of Cell Biology, Winthrop-University Hospital, 222 Station Plaza North, Suite 505-B, Mineola, NY 11501, USA
Neuroreport 12:2623-8. 2001..This novel role of PGD2S, as an inducer of apoptosis, may have implications in PC12 differentiation and possibly some neurological disorders... - Hepatic iron in hemodialysis patientsSteven Fishbane
Kidney Int 66:1714-5. 2004 - Hemoglobin variability in epoetin-treated hemodialysis patientsJeffrey S Berns
Renal, Electrolyte and Hypertension Division, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
Kidney Int 64:1514-21. 2003..This study examines hemoglobin variability under conditions of standard clinical practice in epoetin-treated hemodialysis patients... - Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextranBeckie Michael
Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
Kidney Int 61:1830-9. 2002..S. under FDA's priority drug review. This Phase IV study was designed to evaluate the safety of a single dose of intravenous SFGC as compared to placebo and a historical iron dextran control... - Serum ferritin in chronic kidney disease: reconsidering the upper limit for iron treatmentSteven Fishbane
Semin Dial 17:336-41. 2004..Clinical judgment is critical to properly weigh the risks and benefits of intravenous iron treatment in the context of the individual patient... - The effect of a change in epoetin alfa reimbursement policy on anemia outcomes in hemodialysis patientsJeffrey S Berns
University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19146, USA
Hemodial Int 9:255-63. 2005..The decline in mean weekly dose of epoetin was likely a result of withholding doses out of concern among providers about risk of reimbursement denial... - Evidence and implications of haemoglobin cycling in anaemia managementSteven Fishbane
Nephrol Dial Transplant 22:2129-32. 2007 - Iron management in nondialysis-dependent CKDSteven Fishbane
SUNY at Stony Brook School of Medicine, USA
Am J Kidney Dis 49:736-43. 2007.... - Upper limit of serum ferritin: misinterpretation of the 2006 KDOQI anemia guidelinesSteven Fishbane
Semin Dial 21:217-20. 2008..Instead, clinical judgment is critical to properly weigh risks and benefits of i.v. iron treatment, and to determine whether iron treatment is appropriate for a given patient with higher levels of iron tests... - The optimal hemoglobin in dialysis patients- a critical reviewAjay K Singh
Semin Dial 21:1-6. 2008..We also suggest that the current reimbursement system for erythropoiesis stimulating agent treatment potentially encourages unsafe overtreatment... - History-adjusted marginal structural analysis of the association between hemoglobin variability and mortality among chronic hemodialysis patientsSteven M Brunelli
Renal, Electrolyte and Hypertension Division of the Department of Medicine, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
Clin J Am Soc Nephrol 3:777-82. 2008..The causal nature of this association has been difficult to ascertain because of potential time-dependent confounding, for which traditional statistical methods do not control... - Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patientsRyan D Kilpatrick
Department of Biostatistics and Epidemiology, Amgen Inc, One Amgen Center Drive, MS 24 2 A, Thousand Oaks, CA 91320, USA
Clin J Am Soc Nephrol 3:1077-83. 2008..Among hemodialysis patients, achieved hemoglobin is associated with Epoetin alfa dose and erythropoietin responsiveness. A prospective erythropoietin responsiveness measure was developed and its association with mortality evaluated... - How should chronic medical therapies be altered with the onset of end-stage renal disease and initiation of dialysis?Kathleen L Wyne
Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390-8857, USA
Semin Dial 19:8-24. 2006 - Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patientsDaniel W Coyne
Washington University School of Medicine, St Louis, Missouri 63110, USA
Kidney Int 63:217-24. 2003.... - Safety issues with iron sucroseSteven Fishbane
Am J Kidney Dis 41:899; author reply 900. 2003 - Drug insight: Safety of intravenous iron supplementation with sodium ferric gluconate complexBeckie Michael
Thomas Jefferson University, Philadelphia, PA 19107, USA
Nat Clin Pract Nephrol 2:92-100. 2006..This paper reviews the current literature on the safety of SFGC and examines the emerging safety issues surrounding the use of intravenous iron... - Quality outcomes and obstacles to their achievement in end-stage renal diseaseSteven Fishbane
Semin Dial 15:30-4. 2002..However, there are certain barriers to quality of care that may hinder such efforts. In this article we discuss obstacles to quality of care in ESRD and present potential solutions... - EPO adjuvant treatments: a need for more evidenceSteven Fishbane
Am J Kidney Dis 47:683-5. 2006 - Hemoglobin variability and mortality in ESRDWei Yang
Center for Clinical Epidemiology and Biostatistics and the Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
J Am Soc Nephrol 18:3164-70. 2007..Patient characteristics accounted for very little of the variation in our hemoglobin variability metric (R2 = 0.019). We conclude that greater hemoglobin variability is independently associated with higher mortality... - Cardiovascular risk evaluation before kidney transplantationSteven Fishbane
J Am Soc Nephrol 16:843-5. 2005 - Recombinant human erythropoietin: has treatment reached its full potential?Steven Fishbane
Semin Dial 19:1-4. 2006..In this review the current state of r-HuEPO treatment is compared to the normal biology of erythropoietin and potential pitfalls caused by divergences are explored...